PCSK9 Inhibitors
Author:
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine
Reference44 articles.
1. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia;Abided;Nature Genet,2003
2. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol;Kotowski;Am J Human Genet,2006
3. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease;Cohen;N Engl J Med,2006
4. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events;Sabatine;N Engl J Med,2015
5. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events;Robinson;N Engl J Med,2015
Cited by 94 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Frecuencia y distribución geográfica de la prescripción de inhibidores de PCSK9 en Colombia entre 2019 y 2021;REC: CardioClinics;2024-07
2. World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update;Global Heart;2024
3. Real‐World Effectiveness of PCSK9 Inhibitors in Reducing LDL‐C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries;Journal of the American Heart Association;2023-11-07
4. Role of Circular RNAs in Atherosclerosis through Regulation of Inflammation, Cell Proliferation, Migration, and Apoptosis: Focus on Atherosclerotic Cerebrovascular Disease;Medicina;2023-08-14
5. Effect of Different Types and Dosages of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a) Levels: A Network Meta-analysis;Journal of Cardiovascular Pharmacology;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3